Arcturus Therapeutics is trading 10.27% down at $14.51 after profit-taking following an unusually strong rally.
- Shares rose from $10.28 on August 19 to $16.17 on August 27.
- Recent coverage described the advance as driven by messenger-RNA enthusiasm and company progress, not a new August 28 announcement.
- Biotech is weakening broadly, with XBI down 2.31%; hawkish Federal Reserve messaging is pressuring higher-risk growth stocks, and no clear company-specific catalyst was identified.